{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T09:03:21Z","timestamp":1784711001803,"version":"3.55.0"},"reference-count":44,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2009,1,23]],"date-time":"2009-01-23T00:00:00Z","timestamp":1232668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2009,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>The addition of epidermal growth factor receptor (EGFR) inhibitors to radiotherapy has produced increased locoregional control and has reduced mortality from various solid tumors with few additional toxicities. Although anecdotal reports have suggested increased radiation dermatitis, the overall effect of these regimens on dermatologic toxicities has not been ascertained.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>Dermatologic toxicity data were analyzed from abstracts presented at the annual meetings of the American Society of Clinical Oncology, the American Society of Therapeutic Radiology and Oncology, Cochrane Collaboration, MEDLINE, and EMBASE databases. Phase 1, 2, and 3 trials that reported on radiation dermatitis, rash, and mucositis were included. Collaborative group, phase 3, randomized radiotherapy and chemoradiation trials served as controls. The summary incidence rate and relative risk were calculated using a random\u2010effects or fixed\u2010effects model, depending on the heterogeneity of included studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>The summary incidence of high\u2010grade radiation dermatitis in patients who received radiation plus EGFR inhibitors was 31.3% (95% confidence interval [95% CI], 17.7%\u201049.1%), rash in 16.1% (95% CI, 12.8%\u201020.1%), and mucositis occurred in 52.7% (95% CI, 38.1%\u201066.9%). When the combination of radiotherapy plus EGFR inhibitors was compared with radiation alone, the risk ratio for radiation dermatitis was 2.38 (95% CI, 1.8\u20103.2; <jats:italic>P<\/jats:italic> &lt; .001), rash was 3.01 (95% CI, 2.0\u20104.6; <jats:italic>P<\/jats:italic> &lt; .001), for mucositis it was 1.76 (95% CI, 1.5\u20102.0; <jats:italic>P<\/jats:italic> &lt; .001), suggesting that there was an increased risk of dermatologic toxicities with the combined regimen.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>EGFR inhibitors combined with radiation were associated with a significant increase in the risk for high\u2010grade radiation dermatitis, rash, and mucositis. Although increased rash is expected with EGFR inhibitors, in\u2010field dermatitis and mucositis represent new safety concerns. Improved reporting and management strategies are critical for quality of life and the optimization of radiation plus EGFR inhibitor protocols. Cancer 2009. \u00a9 2009 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.24120","type":"journal-article","created":{"date-parts":[[2009,1,23]],"date-time":"2009-01-23T15:47:13Z","timestamp":1232725633000},"page":"1286-1299","source":"Crossref","is-referenced-by-count":76,"title":["Increased risk of high\u2010grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy"],"prefix":"10.1002","volume":"115","author":[{"given":"Ajay","family":"Tejwani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenhong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxia","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Agulnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Millender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario E.","family":"Lacouture","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,1,23]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1053\/srao.2002.34865"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053422"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-008-1829-z"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc071075"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2007.09.003"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.4045"},{"issue":"1","key":"e_1_2_6_8_2","article-title":"Cetuximab (C\u2010MoAb) and chemo\u2010radiation (CT\u2010RT) for loco\u2010regional advanced squamous cell carcinoma of the head and neck (HNC): a phase II study [abstract]. 2007 ASCO Annual Meeting Proceedings","volume":"25","author":"Merlano MC","year":"2007","journal-title":"J Clin Oncol."},{"issue":"18","key":"e_1_2_6_9_2","article-title":"Phase II study of erlotinib combined with cisplatin and radiotherapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN) [abstract]. 2007 ASCO Annual Meeting Proceedings","volume":"25","author":"Herchenhorn D","year":"2007","journal-title":"J Clin Oncol."},{"issue":"18","key":"e_1_2_6_10_2","article-title":"Phase II trial of docetaxel (T), cisplatin (P), and cetuximab (E) followed by concurrent radiation (RT), P, and E in locally advanced head and neck squamous cell carcinoma (HNSCC) [abstract]. 2007 ASCO Annual Meeting Proceedings","volume":"25","author":"Argiris A","year":"2007","journal-title":"J Clin Oncol."},{"issue":"18","key":"e_1_2_6_11_2","article-title":"Induction cetuximab (C) followed by C, paclitaxel (P), carboplatin (CP) and concurrent radiation (RT) for locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN) [abstract]. 2007 ASCO Annual Meeting Proceedings","volume":"24","author":"Birnbaum AE","year":"2007","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.07.024"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.00.1792"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.07.1588"},{"issue":"18","key":"e_1_2_6_15_2","article-title":"Phase II evaluation of cetuximab (C225) combined with induction paclitaxel and carboplatin followed by C225, paclitaxel, carboplatin, and radiation for stage III\/IV operable squamous cancer of the head and neck (ECOG, E2303) [abstract]. 2007 ASCO Annual Meeting Proceedings","volume":"25","author":"Wanebo HJ","year":"2007","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.07.1581"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.07.1632"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.13.3234"},{"issue":"18","key":"e_1_2_6_19_2","article-title":"Pilot phase I study of gefitinib (GEF) in combination with paclitaxel (PAC) and radiation therapy (RT) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC) and effects on epidermal growth factor receptor (EGFR) signaling pathway [abstract]. 2007 ASCO Annual Meeting Proceedings","volume":"25","author":"Morris JC","year":"2007","journal-title":"J Clin Oncol."},{"issue":"18","key":"e_1_2_6_20_2","article-title":"Phase I study of panitumumab, chemotherapy and intensity\u2010modulated radiotherapy (IMRT) for head and neck cancer (HNC): early results [abstract]. 2007 ASCO Annual Meeting Proceedings","volume":"25","author":"Wirth LJ","year":"2007","journal-title":"J Clin Oncol."},{"issue":"18","key":"e_1_2_6_21_2","article-title":"Cetuximab in combination with intensity modulated radiotherapy (IMRT) and gemcitabine for patients with locally advanced pancreatic cancer: a prospective phase II trial (PARC\u2010Study ISRCTN56652283) [abstract]. 2007 ASCO Annual Meeting Proceedings","volume":"25","author":"Krempien R","year":"2007","journal-title":"J Clin Oncol."},{"issue":"18","key":"e_1_2_6_22_2","article-title":"Early analysis of toxicity and surgery in patients treated with cetuximab single agent followed by 5\u2010FU, cetuximab and pelvic radiotherapy as neo\u2010adjuvant treatment for operable, locally advanced rectal cancer (RC) [abstract]. 2007 ASCO Annual Meeting Proceedings","volume":"25","author":"Bertolini F","year":"2007","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.07.105"},{"issue":"18","key":"e_1_2_6_24_2","article-title":"Cetuximab, capecitabine, and oxaliplatin (Cet\u2010CapOx) with concurrent radiotherapy (RT) in advanced rectal cancer (RC): results of a phase I\/II trial [abstract]. 2007 ASCO Annual Meeting Proceedings","volume":"25","author":"Arnold D","year":"2007","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl460"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.07.1730"},{"issue":"18","key":"e_1_2_6_27_2","article-title":"Safety study of induction chemotherapy and synchronous radiotherapy (RT) and cetuximab in stage III non\u2010small cell lung cancer (NSCLC): SCRATCH (Cohort I) [abstract]. 2007 ASCO Annual Meeting Proceedings","volume":"25","author":"Hughes SR","year":"2007","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.cad.0000185178.26862.4c"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.coc.0000184682.51193.00"},{"issue":"18","key":"e_1_2_6_30_2","article-title":"Erlotinib (E), cisplatin (C) and radiotherapy (RT) for patients with locally advanced squamous cell cervical cancer\u2014a phase I trial [abstract]. 2007 ASCO Annual Meeting Proceedings","volume":"25","author":"Rodrigues AN","year":"2007","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_31_2","volume-title":"Common Terminology Criteria for Adverse Events version 3.0 (CTCAE)","author":"National Cancer Institute","year":"2006"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-127-9-199711010-00008"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.01.008"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032646"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032641"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031317"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-3-5"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1970"},{"key":"e_1_2_6_40_2","doi-asserted-by":"crossref","unstructured":"BonnerJA HarariPM GiraltJ et al.Duration of mucositis and dysphagia following radiotherapy (+cetuximab) for locoregionally advanced head and neck cancer. Presented at the Inaugural ASTRO\/ASCO\/AHNS Multidisciplinary Head and Neck Cancer Symposium Rancho Mirage Calif January 18\u201020 2007.","DOI":"10.1016\/j.ijrobp.2007.06.005"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.04.062"},{"issue":"11","key":"e_1_2_6_42_2","first-page":"34","article-title":"Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist's perspective. Impact on health\u2010related quality of life and implications for clinical management of psychological sequelae","volume":"21","author":"Wagner LI","year":"2007","journal-title":"Oncology (Williston Park)."},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.8005"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.6987"},{"issue":"18","key":"e_1_2_6_45_2","article-title":"Does tetracycline prevent\/palliate epidermal growth factor receptor (EGFR) inhibitor\u2010induced rash? A phase III trial from the North Central Cancer Treatment Group (N03CB) [abstract]. 2007 ASCO Annual Meeting Proceedings","volume":"25","author":"Jatoi A","year":"2007","journal-title":"J Clin Oncol."}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.24120","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.24120","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T18:59:09Z","timestamp":1760295549000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.24120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,23]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,3,15]]}},"alternative-id":["10.1002\/cncr.24120"],"URL":"https:\/\/doi.org\/10.1002\/cncr.24120","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,23]]}}}